Back to Search
Start Over
Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)
- Source :
- Journal of Antimicrobial Chemotherapy
- Publication Year :
- 2021
- Publisher :
- Oxford University Press (OUP), 2021.
-
Abstract
- Background: The combination of sofosbuvir (SOF) and daclatasvir (DCV) has shown preliminary efficacy for patients with COVID-19 in five open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir and daclatasvir to standard care improved clinical endpoints in hospitalized patients with moderate or severe COVID-19. Methods: This was a placebo-controlled, randomized clinical trial in adults with moderate or severe COVID-19 admitted to 19 hospitals in Iran. Patients were randomized to SOF/DCV 400/60mg once-daily or placebo in addition to standard of care. Patients were included if they had positive PCR or diagnostic chest CT, O 2 saturation
- Subjects :
- Adult
Microbiology (medical)
medicine.medical_specialty
Pyrrolidines
Randomization
Daclatasvir
Coronavirus disease 2019 (COVID-19)
Sofosbuvir
Placebo
Antiviral Agents
law.invention
Randomized controlled trial
law
Internal medicine
Clinical endpoint
AcademicSubjects/MED00740
Humans
Medicine
Pharmacology (medical)
Original Research
Pharmacology
SARS-CoV-2
business.industry
Imidazoles
COVID-19
Valine
Institutional review board
Clinical trial
AcademicSubjects/MED00290
Treatment Outcome
Infectious Diseases
Relative risk
Carbamates
AcademicSubjects/MED00230
business
medicine.drug
Subjects
Details
- ISSN :
- 14602091 and 03057453
- Volume :
- 77
- Database :
- OpenAIRE
- Journal :
- Journal of Antimicrobial Chemotherapy
- Accession number :
- edsair.doi.dedup.....f69baf1a0987326edb8a47d694d9afe2